Abstract: The present technology provides 3,3-difluoroallylamines or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. The 3,3-difluoroallylamines or their pharmaceutically acceptable salts exhibit potent inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

Abstract: This application relates to a device and a method for voice-based trauma screening using deep learning. The device and method for voice-based trauma screening using deep learning screen for trauma through voices that may be obtained in a non-contact manner without limitations of space or situation. In one aspect, the device includes a memory configured to store at least one program and a processor configured to perform an operation by executing the at least one program. The processor can obtain voice data, pre-process the voice data, convert pre-processed voice data into image data, and input the image data to a deep learning model and obtain a trauma result value as an output value of the deep learning model.

Abstract: The present technology provides 3,3-difluoroallylamines or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. The 3,3-difluoroallylamines or their pharmaceutically acceptable salts exhibit potent inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

Abstract: The present technology provides 3,3-difluoroallylamines or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. The 3,3-difluoroallylamines or their pharmaceutically acceptable salts exhibit potent inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

Abstract: This application relates to a device and a method for voice-based trauma screening using deep learning. The device and method for voice-based trauma screening using deep learning screen for trauma through voices that may be obtained in a non-contact manner without limitations of space or situation. In one aspect, the device includes a memory configured to store at least one program and a processor configured to perform an operation by executing the at least one program. The processor can obtain voice data, pre-process the voice data, convert pre-processed voice data into image data, and input the image data to a deep learning model and obtain a trauma result value as an output value of the deep learning model.

Abstract: The present technology provides 3,3-difluoroallylamines or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. The 3,3-difluoroallylamines or their pharmaceutically acceptable salts exhibit potent inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

Abstract: The present technology provides triazolone derivatives or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and the use thereof. The triazolone derivatives or their pharmaceutically acceptable salts exhibit selective inhibitory activity on VAP-1 and therefore can be usefully applied, e.g. for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

Abstract: The present technology provides triazolone derivatives or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and the use thereof. The triazolone derivatives or their pharmaceutically acceptable salts exhibit selective inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

Abstract: The present technology provides 3,3-difluoroallylamines or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. The 3,3-difluoroallylamines or their pharmaceutically acceptable salts exhibit potent inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

Abstract: The present technology provides triazolone derivatives or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and the use thereof. The triazolone derivatives or their pharmaceutically acceptable salts exhibit selective inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

Abstract: A method of processing a blood vessel image is provided. The method includes (a) sharpening an original blood vessel image using a Gabor filter in consideration of various directions and thicknesses of blood vessels included in the blood vessel and (b) detecting edges according to a change in brightness in a blood vessel domain and a non-blood vessel domain of the original blood vessel image and the blood vessel image on which the Gabor filtering step is completed, using an edge extraction method based on a first-order differentiation or second-order differentiation.

Abstract: A method of processing a blood vessel image is provided. The method includes (a) sharpening an original blood vessel image using a Gabor filter in consideration of various directions and thicknesses of blood vessels included in the blood vessel and (b) detecting edges according to a change in brightness in a blood vessel domain and a non-blood vessel domain of the original blood vessel image and the blood vessel image on which the Gabor filtering step is completed, using an edge extraction method based on a first-order differentiation or second-order differentiation.

Abstract: A method of biometric authentication based on unique information obtained from a pupil. The method includes: acquiring an image of a pupil and an iris; extracting a pupil region from the image; and generating unique biometric information by extracting a specific pattern of the pupil from the pupil region. The method performs biometric authentication by combining unique information obtained from a pupil region with unique information obtained from an iris region.

Abstract: A gaze position tracking method and apparatus for simply mapping one's gaze position on a monitor screen are provided. The gaze position tracking apparatus includes an image capturing module, and an image processing module. The image capturing module illuminates infrared rays to a user's eyes, reflects an illuminated eye image at 45°, and captures the 45° reflected eye image. The image processing module obtains a pupil center point of the illuminated eye image by performing a predetermined algorithm, and maps the pupil center point on a display plane of a display device through a predetermined transform function.